Literature DB >> 4104441

A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy.

J E Castro, H J Griffiths, D E Edwards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4104441     DOI： 10.1002/bjs.1800580703

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


× No keyword cloud information.
  7 in total

Review 1.  Benign prostatic hyperplasia: the best treatment.

Authors:  G D Chisholm
Journal:  BMJ       Date:  1989-07-22

2.  Pills for the benign prostate. Trial designs.

Authors:  J E Castro
Journal:  Proc R Soc Med       Date:  1972-02

3.  Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

Review 4.  A clinical view of pressure-flow studies.

Authors:  J Nordling
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

5.  Candicidin treatment of prostatism: a prospective double-blind placebo-controlled study.

Authors:  K M Jensen; P O Madsen
Journal:  Urol Res       Date:  1983

6.  Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation.

Authors:  F Ronchi; A Margonato; R Ceccardi; P Rigatti; B M Rossini
Journal:  Urol Res       Date:  1982

7.  Definition of prostatic urethral obstruction.

Authors:  J Nordling
Journal:  Urol Res       Date:  1994
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.